Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 3SBio Submits Application for Phase I NuPIAO Trial | Contract Pharma

What are you searching for?

Sign in

3SBio Submits Application for Phase I NuPIAO Trial

3SBio Inc. has submitted its application for a Phase I trial for NuPIAO to the Chinese State Food and Drug Administration (SFDA).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

3SBio Inc. has submitted its application for a Phase I trial for NuPIAO to the Chinese State Food and Drug Administration (SFDA). NuPIAO is a highly glycosylated ESA (erythropoiesis-stimulating agent) with extended half-life and increased biologic activity. Preclinical results have showed a promising pharmacokinetic profile, which would allow a once weekly injection schedule. The drug will be studied as a potential treatment for anemia associated with both chronic kidney disease and cancer.

“This submission represents another important milestone in our effort to extend our market leading EPO franchise and continue to serve the needs of patients in China,” said Dr. Jing Lou, chief executive officer of 3SBio. “It is a direct result of our dedicated R&D effort to generate an innovative pipeline and create long term value for shareholders.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters